Logo image of PLRX

PLIANT THERAPEUTICS INC (PLRX) Stock Fundamental Analysis

NASDAQ:PLRX - Nasdaq - US7291391057 - Common Stock - Currency: USD

3.08  +0.07 (+2.33%)

After market: 3.0314 -0.05 (-1.58%)

Fundamental Rating

2

Overall PLRX gets a fundamental rating of 2 out of 10. We evaluated PLRX against 194 industry peers in the Pharmaceuticals industry. PLRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PLRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PLRX had negative earnings in the past year.
PLRX had a negative operating cash flow in the past year.
In the past 5 years PLRX always reported negative net income.
In the past 5 years PLRX always reported negative operating cash flow.
PLRX Yearly Net Income VS EBIT VS OCF VS FCFPLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -45.25%, PLRX is not doing good in the industry: 60.54% of the companies in the same industry are doing better.
The Return On Equity of PLRX (-58.32%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -45.25%
ROE -58.32%
ROIC N/A
ROA(3y)-36.88%
ROA(5y)-26.09%
ROE(3y)-40.76%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
PLRX Yearly ROA, ROE, ROICPLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

PLRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLRX Yearly Profit, Operating, Gross MarginsPLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

PLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PLRX has more shares outstanding
PLRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PLRX has an improved debt to assets ratio.
PLRX Yearly Shares OutstandingPLRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
PLRX Yearly Total Debt VS Total AssetsPLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

PLRX has an Altman-Z score of -1.62. This is a bad value and indicates that PLRX is not financially healthy and even has some risk of bankruptcy.
PLRX has a Altman-Z score of -1.62. This is comparable to the rest of the industry: PLRX outperforms 45.95% of its industry peers.
PLRX has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
PLRX's Debt to Equity ratio of 0.09 is in line compared to the rest of the industry. PLRX outperforms 48.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -1.62
ROIC/WACCN/A
WACC10.03%
PLRX Yearly LT Debt VS Equity VS FCFPLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M 400M

2.3 Liquidity

PLRX has a Current Ratio of 10.26. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.26, PLRX belongs to the best of the industry, outperforming 83.24% of the companies in the same industry.
PLRX has a Quick Ratio of 10.26. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PLRX (10.26) is better than 83.24% of its industry peers.
Industry RankSector Rank
Current Ratio 10.26
Quick Ratio 10.26
PLRX Yearly Current Assets VS Current LiabilitesPLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

PLRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.71%.
Looking at the last year, PLRX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
The Revenue for PLRX have been decreasing by -66.44% on average. This is quite bad
EPS 1Y (TTM)-19.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.71%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-66.44%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PLRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.53% yearly.
Based on estimates for the next years, PLRX will show a very strong growth in Revenue. The Revenue will grow by 139.09% on average per year.
EPS Next Y-34.25%
EPS Next 2Y-17.72%
EPS Next 3Y-10.4%
EPS Next 5Y4.53%
Revenue Next Year-100%
Revenue Next 2Y1.13%
Revenue Next 3Y38.05%
Revenue Next 5Y139.1%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PLRX Yearly Revenue VS EstimatesPLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
PLRX Yearly EPS VS EstimatesPLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PLRX. In the last year negative earnings were reported.
Also next year PLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLRX Price Earnings VS Forward Price EarningsPLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLRX Per share dataPLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PLRX's earnings are expected to decrease with -10.40% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.72%
EPS Next 3Y-10.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PLRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLIANT THERAPEUTICS INC

NASDAQ:PLRX (2/21/2025, 4:45:12 PM)

After market: 3.0314 -0.05 (-1.58%)

3.08

+0.07 (+2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners118.07%
Inst Owner Change0.05%
Ins Owners2.34%
Ins Owner Change2.97%
Market Cap187.42M
Analysts85.26
Price Target40.29 (1208.12%)
Short Float %12.31%
Short Ratio4.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.21%
Min EPS beat(2)-6.32%
Max EPS beat(2)3.9%
EPS beat(4)3
Avg EPS beat(4)3.84%
Min EPS beat(4)-6.32%
Max EPS beat(4)16.88%
EPS beat(8)6
Avg EPS beat(8)3.93%
EPS beat(12)9
Avg EPS beat(12)4.73%
EPS beat(16)11
Avg EPS beat(16)4.89%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)-66.24%
Revenue beat(12)4
Avg Revenue beat(12)-19.67%
Revenue beat(16)5
Avg Revenue beat(16)-19.76%
PT rev (1m)0.42%
PT rev (3m)-1.7%
EPS NQ rev (1m)0.57%
EPS NQ rev (3m)-8.27%
EPS NY rev (1m)0.16%
EPS NY rev (3m)0.13%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-3.34
EYN/A
EPS(NY)-3.82
Fwd EYN/A
FCF(TTM)-2.25
FCFYN/A
OCF(TTM)-2.18
OCFYN/A
SpS0
BVpS5.68
TBVpS5.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.25%
ROE -58.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.88%
ROA(5y)-26.09%
ROE(3y)-40.76%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 173.87%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.26
Quick Ratio 10.26
Altman-Z -1.62
F-Score1
WACC10.03%
ROIC/WACCN/A
Cap/Depr(3y)91.12%
Cap/Depr(5y)95.33%
Cap/Sales(3y)34.07%
Cap/Sales(5y)21.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.71%
EPS Next Y-34.25%
EPS Next 2Y-17.72%
EPS Next 3Y-10.4%
EPS Next 5Y4.53%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-66.44%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y1.13%
Revenue Next 3Y38.05%
Revenue Next 5Y139.1%
EBIT growth 1Y-27.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.39%
EBIT Next 3Y-19.4%
EBIT Next 5YN/A
FCF growth 1Y-59.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.69%
OCF growth 3YN/A
OCF growth 5YN/A